摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(pentyloxycarbonyl)imidazole

中文名称
——
中文别名
——
英文名称
1-(pentyloxycarbonyl)imidazole
英文别名
Pentyl imidazole-1-carboxylate
1-(pentyloxycarbonyl)imidazole化学式
CAS
——
化学式
C9H14N2O2
mdl
——
分子量
182.222
InChiKey
ZSGUTMRPWMEMAS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    13
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    [EN] ONE STEP PROCESS FOR THE PREPARATION OF CAPECITABINE
    [FR] PROCÉDÉ EN UNE ÉTAPE POUR LA PRÉPARATION DE LA CAPÉCITABINE
    摘要:
    本发明涉及一种制备卡培他滨及其类似物的一步法过程,如加洛他滨、萨帕他滨、5'-去氧-5-氟-N-[(环己氧)羰基]胞苷和N-[(庚氧)羰基]胞嘧啶。
    公开号:
    WO2011104540A1
  • 作为产物:
    描述:
    氯甲酸正戊酯 以70的产率得到1-(pentyloxycarbonyl)imidazole
    参考文献:
    名称:
    [EN] ONE STEP PROCESS FOR THE PREPARATION OF CAPECITABINE
    [FR] PROCÉDÉ EN UNE ÉTAPE POUR LA PRÉPARATION DE LA CAPÉCITABINE
    摘要:
    本发明涉及一种制备卡培他滨及其类似物的一步法过程,如加洛他滨、萨帕他滨、5'-去氧-5-氟-N-[(环己氧)羰基]胞苷和N-[(庚氧)羰基]胞嘧啶。
    公开号:
    WO2011104540A1
点击查看最新优质反应信息

文献信息

  • CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
    申请人:Cole Roderic O.
    公开号:US20140357557A1
    公开(公告)日:2014-12-04
    Methods and compositions relating to CDP-JAK inhibitor conjugates are described herein.
    这里描述了与CDP-JAK抑制剂共轭物相关的方法和组合物。
  • NOVEL HETEROCYCLYL COMPOUNDS
    申请人:Aebi Johannes
    公开号:US20100016282A1
    公开(公告)日:2010-01-21
    The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y 1 , Y 2 , Y 3 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
    该发明涉及式(I)的新异环丙基化合物,其中A、X、Y1、Y2、Y3、R3、R4、R5、R6、R7、R8、R9、R10、m、n和p的定义如描述和索赔中所述,并且其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂,可以用作药物。
  • [EN] CYCLIC SULPHINYL ESTERS OF CYTIDINE<br/>[FR] ESTERS SULFINYLE CYCLIQUES DE CYTIDINE
    申请人:GENERICS UK LTD
    公开号:WO2011067588A1
    公开(公告)日:2011-06-09
    The present invention relates to novel intermediates and to an improved process for the preparation of N- functionalised cytidine derivatives such as capecitabine, galocitabine and sapacitabine. Said intermediates are se from a copound of formula (A- 2), (A-3), (A-6), (A-7). wherein: R1 and R3 arc each independendy selected from hydrogen, -F, -CI, -Br, -I, -CN, -NO2, -N3, -O-R7, -S-R7, -N(R7)2, -N(R7)3+ or -0-Si(R7)3; R4 and R5 arc each independendy selected from hydrogen, -F, -CI, -Br and -I; R6 is selected from an alkyl, alkenyl, alkynyl, atyl, aiylalkyl, arylalkenyl, arylalkynyl, alkylaiyl, alkenylaryl or alkynylaryl group, each of which may optionally be substituted, and each of which may optionally include one or more heteroatoms N, O or S in its carbon skeleton; and each R7 is independendy selected from hydrogen, or an alkyl, alkenyl, alkynyl, atyl, aiylalkyl, arylalkenyl, arylalkynyl, alkylaiyl, alkenylaryl or alkynylaryl group, each of which may optionally he substituted, and each of which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, and wherein any two or more R7 groups may, together with rhe atom or atoms to which they are attached, form a cyclic alkyl, alkenyl, alkynyl, aryl, aiylalkyl, arylalkcnyl, arylalkynyl, alkylaiyl, alkenylaryl or alkynylaryl group, each of which may optionally be substituted, and each of which may optionally include one or more heteroatoms N, O or S in its carbon skeleton.
    本发明涉及新型中间体和改进的制备N-功能化胞嘧啶生物(如卡培他滨加洛他滨和萨帕他滨)的过程。所述中间体是从化合物(A-2),(A-3),(A-6),(A-7)中选择的。其中:R1和R3各自独立地选自氢,-F,-CI,-Br,-I,-CN,-NO2,-N3,-O-R7,-S-R7,-N(R7)2,-N(R7)3+或-0-Si(R7)3; R4和R5各自独立地选自氢,-F,-CI,-Br和-I; R6选自烷基,烯烃基,炔基,芳基,取代的芳基烷基,取代的芳基烯烃基,取代的芳基炔基,烷基芳基,烯烃基芳基或炔基芳基基团,其中每个基团可以选择性地被取代,并且每个基团可以选择性地包含一个或多个N,O或S杂原子在其碳骨架中; 每个R7独立地选自氢,或烷基,烯烃基,炔基,芳基,取代的芳基烷基,取代的芳基烯烃基,取代的芳基炔基,烷基芳基,烯烃基芳基或炔基芳基基团,其中每个基团可以选择性地被取代,并且每个基团可以选择性地包含一个或多个N,O或S杂原子在其碳骨架中,任何两个或多个R7基团可以与它们附着的原子一起形成环烷基,烯烃基,炔基,芳基,取代的芳基烷基,取代的芳基烯烃基,取代的芳基炔基,烷基芳基,烯烃基芳基或炔基芳基基团,其中每个基团可以选择性地被取代,并且每个基团可以选择性地包含一个或多个N,O或S杂原子在其碳骨架中。
  • Synthesis of Tertiary Amines through Extrusive Alkylation of Carbamates
    作者:Guoliang Zhang、David Favela、Winston L. Chow、Rishab N. Iyer、Alexander J. Pell、David E. Olson
    DOI:10.1021/acs.orglett.2c02516
    日期:2022.8.26
    Basic amines are key elements of many biologically active natural products and pharmaceuticals. Given their inherent reactivity, it is often necessary to protect basic amines during target-directed synthesis, which results in wasteful protection/deprotection sequences. We report a step-economical approach enabling the protection of secondary amines as carbamates prior to their conversion to tertiary
    碱性胺是许多具有生物活性的天然产物和药物的关键元素。鉴于其固有的反应性,在靶向合成过程中通常需要保护碱性胺,这会导致保护/脱保护序列的浪费。我们报告了一种分步经济的方法,能够在仲胺通过 CO 2的正式挤出转化为叔胺之前将其保护为氨基甲酸酯。该方法适用于 iboga 生物碱 (±)-conodusine A 和 (±)-conodusine B 的合成。
  • Trotta, Francesco; Moraglio, Giovanni; Marzona, Mario, Gazzetta Chimica Italiana, 1993, vol. 123, # 10, p. 559 - 562
    作者:Trotta, Francesco、Moraglio, Giovanni、Marzona, Mario、Maritano, Silvana
    DOI:——
    日期:——
查看更多